Johnson & Johnson (NYSE: JNJ) is in the process of completing its $30 billion acquisition of Swiss biotech Actelion and is expected to close in the second quarter of FY 17 after getting all the approvals. The company has obtained regulatory approval in six of seven jurisdictions in which the company filed for such approval, with antitrust approval from the European Commission pending. Johnson & Johnson is looking forward to the associates from Actelion joining the Johnson & Johnson Family of Companies. Further, Johnson & Johnson first quarter result is in line with the company’s expectation. Johnson & Johnson has included the estimated impact of the Actelion transaction in its financial guidance for FY 17. Therefore, Johnson & Johnson has increased its sales guidance for the full-year 2017 to be in the range of $75.4 billion to $76.1 billion. The company has also increased its adjusted earnings per share guidance for full-year 2017 to be in the range of $7.00 – $7.15. The analysts are expecting the FY2017 earnings per share of $7.06, and the revenue of $74.88 billion.

Moreover, in the first quarter, Johnson & Johnson has completed the acquisition of Abbott Medical Optics, which is a wholly-owned subsidiary of Abbott and global leader in ophthalmic surgery, for approximately $4.3 billion. Additionally, JNJ has completed the acquisitions of Megadyne Medical Products, Inc., a privately held medical device company that develops, manufactures and markets electrosurgical tools, and Torax Medical Inc., a privately held medical device company that manufactures and markets the LINX(TM) Reflux Management System for the surgical treatment of gastroesophageal reflux disease. In April, subsequent to the quarter, JNJ has completed the acquisition of Neuravi Limited, a privately held medical device company that develops and markets medical devices for neurointerventional therapy.

Meanwhile, Johnson & Johnson in the first quarter of FY 17 has reported the adjusted earnings per share of $1.61, missing the analysts’ estimates for the adjusted earnings per share of $1.76. The company had reported the adjusted revenue growth of 1.6 percent to $17.8 billion in the first quarter of FY 17, missing the analysts’ estimates for revenue of $18.02 billion.

Johnson & Johnson stock has risen 14.1% in the last one year (source: Google Finance) but lost over 3.1% this morning (as of  10:30AM EDT on April 18th, 2017; Source: Google finance). The stock has limited upside of 3.88% for an average price target of $130.60 as per tipranks.com.